Affordable Risdiplam for Spinal Muscular Atrophy (SMA), Now Available on MedsPartner

Summary: This guide shares the latest as of October 2025 on how you can access affordable generic Risdiplam for Spinal Muscular Atrophy (SMA) through MedsPartner. It explains what Risdiplam does, the new India pricing development, how compliant personal import works, typical insurance hurdles, and how you can cut costs safely without compromising on quality.

Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the motor neurons responsible for muscle movement. It causes progressive muscle weakness and loss of mobility and is one of the leading causes of infant mortality worldwide. Despite new treatments, the cost of managing SMA remains extraordinarily high. Life-saving meds like Evrysdi® can cost millions of dollars over a patient’s lifetime, making access a roadblock for families.

But finally, there is a ray of hope for SMA patients and caregivers! A low-cost generic version of Risdiplam is now launching in India, following a Delhi High Court ruling. Now, through MedsPartner’s compliant personal import program, patients around the world can legally access this life-changing SMA medicine at 90% lower cost than branded Evrysdi®. This blog highlights these affordable treatment options and access pathways for SMA.

What is Risdiplam? How does it work for SMA patients?

Risdiplam is the generic version of Evrysdi®, an oral treatment for children and adults living with Spinal Muscular Atrophy. SMA is caused by low levels of the SMN protein. Risdiplam modifies SMN2 pre-mRNA splicing so your body makes more full-length SMN protein. 

Higher SMN levels support motor neurons and can stabilise or improve motor function. The FDA first approved Evrysdi® in 2020 for patients 2 months and older and later expanded the label for younger infants and added a tablet form in 2025. 

What recent clinical data says about Risdiplam for SMA treatment 

Long-term SMA trials show sustained benefit with Risdiplam across key cohorts. FIREFISH in infantile onset SMA reported maintained or improved motor outcomes over multi-year follow-up. SUNFISH presented four-year efficacy and safety data in Types 2 and 3. These readouts reinforce why continuity of therapy matters and why affordability is pivotal for families. Additional studies like JEWELFISH in previously treated patients and ongoing combination research aim to optimise function further, which makes uninterrupted access and consistent dosing even more important.

Why is branded Evrysdi® expensive in places like the USA?

SMA is a rare disease with orphan drug protections and limited competition. The originator invested in complex trials that ran across multiple SMA types. Add speciality manufacturing and distribution with small patient populations, and the result is very high retail prices. 

As a result, the monthly cost of Evrysdi® runs into tens of thousands of dollars in the USA. Speciality pharmacy markups, prior authorisation requirements and limited formulary placement further raise out-of-pocket costs for many insured families.

What has made Risdiplam affordable in 2025?

A Delhi High Court bench has allowed Natco Pharma to launch a generic Risdiplam in India at a small fraction of the cost of the branded drug. This ruling opens up a reliable supply route that many international patients can also use through compliant personal importation. 

Risdiplam vs. Evrysdi® - Cost comparison for a typical month

Buying the verified generic Risdiplam through MedsPartner costs about $260 for 80 mL, compared to roughly $13,157 for the same volume of branded Evrysdi® in the U.S. This translates to an estimated 98% savings on equivalent dosage.

Real-world impact of generic Risdiplam on SMA patients

Millions of families worldwide struggle with the high cost of Evrysdi. The human toll is stark. As SMA patient and advocate Sherry Toh bluntly puts it, “I’ve affixed a price tag to my life.” 

At MedsPartner, we’ve already helped over 30,000 patients across 45+ countries gain affordable access to essential medicines for rare diseases. And now, we’re proud to extend that support to the SMA community, making treatment more accessible and hopeful for patients everywhere.

“We hope this judgement will pave the way for affordable access for SMA patients.” - Purva Mittal (patient advocate). 

How can you access affordable generic Risdiplam through MedsPartner?

Many countries allow personal import for your own treatment when local options are unaffordable or unavailable. You will need a valid prescription from your treating clinician. Quantity limits typically cap at up to a 90-day supply per shipment. MedsPartner verifies the prescription and your local regulations, sources the medicines from reputed manufacturers and ships them in compliance with your country’s rules. We support you with all the paperwork and steps needed for customs clearance.

Insurance hurdles with Evrysdi® and practical next steps

Insurers often apply prior authorisation rules for Evrysdi®, and many plans set very high copays. Manufacturer support may help some families, but not all. Genentech’s MySMA Support and Access Solutions share information on financial help and navigation. 

If your plan denies coverage or your out-of-pocket cost remains unworkable, generic Risdiplam via compliant personal import can close the gap quickly and safely. When applying, you should include the genetic report, clinic notes, motor scores and any intolerance to alternatives, and attach a formal quote for generic Risdiplam as a lower-cost option to avoid treatment interruption.

Answering your FAQs on Risdiplam and access

Q1. Is generic Risdiplam as effective as branded Evrysdi®?

A. Yes. Generic Risdiplam contains the same active ingredient and is bioequivalent when sourced from qualified manufacturers. MedsPartner supplies from FDA or EMA-approved facilities and shares batch details for your safety and peace of mind.

Q2. How much does generic Risdiplam cost compared with Evrysdi®?

A. Generic Risdiplam through MedsPartner costs about $260 for 80 mL, compared to ~$13,157 for the same volume of branded Evrysdi® in the U.S. This translates to an estimated 98% savings on equivalent dosage.

Q3. Is it legal to import Risdiplam for personal use?

A. Many countries permit personal import with a valid prescription and in small quantities for your own treatment. Most regions allow up to a 90-day supply per parcel for a named patient and require clear non-resale declarations. MedsPartner prepares the required paperwork and supports customs clearance in line with your local rules. 

Q4. What if insurance denies Evrysdi® or the copay is too high?

A. You can appeal to your neurologist and submit clinical notes and genetic reports. You can also check manufacturer help through MySMA Support. If coverage still fails or the copay stays unaffordable, you can use MedsPartner to access generic Risdiplam through compliant import at a fraction of the cost. 

Q5. How does MedsPartner provide safe, high-quality Risdiplam?

A. Medspartner offers compliant personal importation of affordable Risdiplam for SMA treatment. We source high-quality medicines exclusively from FDA/EMA-approved manufacturers and run stringent quality checks on each batch before dispatch. Your order is shipped with all required product documentation through reputed logistics partners for end-to-end traceability. 

Looking to access Risdiplam at an affordable price? 

Write to us if you need guidance on compliant personal import of generic Risdiplam. You can reduce your monthly financial burden without skipping treatment. Our team is here to support you with information on import rules, prices, and the ordering process.

Author Bio - Mrinalini Sachan is a medical content writer with over a decade of experience writing on MedTech, pharma, and healthcare topics. She specializes in transforming complex clinical subjects into clear, informative content for patients and caregivers, developing content with a commitment to improve global healthcare and drive positive societal change.